Axil Capital
VC Fund
Tokyo, Japan
Axil Capital is a venture capital firm investing in companies in the biomedical and healthcare fields from the early stages.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 39%
Last updated:
For AI agents: llms.txt
Industries Axil Capital invests in
Stages Axil Capital invests in
Countries Axil Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $9.8M–$55M
- Series B
- $7M–$150M
- Series C
- $3.1M–$62M
Investment Focus
Industry
- Health Care 13 (57%)
- Medical 9 (39%)
- Biotechnology 9 (39%)
- Pharmaceutical 4 (17%)
- Medical Device 3 (13%)
Stage
- Series A 5 (22%)
- Series B 5 (22%)
- Series C 5 (22%)
- Seed 3 (13%)
- Funding Round 2 (9%)
Country
- Japan 13 (57%)
- United States 4 (17%)
- Israel 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Fred Shane
Managing Partner & Co-Founder
|
Managing Partner & Co-Founder | Total investments: 4 | Find email | |
Hiroshi Gonaikawa
Co-Founder & Partner
|
Co-Founder & Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| DT Axis is a digital health firm that focuses on the research, development, and distribution of medical software, namely in the field of digital therapeutics. | Seed / Dec 09, 2025 | ||
| Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $9.5M / Series B / Jan 10, 2025 | ||
| MabGenesis is a biopharmaceutical company that provides therapeutic monoclonal antibody drugs in human and animal fields. | $3M / Venture - Series Unknown / Dec 24, 2024 | ||
| Red Arrow Therapeutics is a biotech firm that provides systemic cytokine delivery, targeted intratumoral activation, and biological potency. | $55M / Series A / Sep 18, 2024 | ||
| Hirosaki Lifescience Innovation is engaged in the development, manufacture, and sale of regenerative medicine products. | $15.2M / Series C / Jul 22, 2024 | ||
| GEXVal is to help patients and families fighting against orphan and intractable diseases | $3.1M / Series C / Dec 04, 2023 | ||
| Cranebio specializes in development of a wearable health care kit, device-free genetic test kit, and rapid environmental test kit. | $35.4M / Series A / Oct 04, 2023 | ||
| Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system. | $20.3M / Series C / Jun 06, 2023 | ||
| AIBIOS has designed and developed a series of novel small molecules which modulate both the innate (macrophages) and adaptive immune system to treat therapeutic indications of Gastroenterology, Respiratory, and Neurological diseases. | $4.6M / Seed / Apr 28, 2021 | ||
| Suono Bio is developing platform technology designed to enable ultra-rapid delivery of therapeutics, including proteins and nucleic acids, to the gastrointestinal (GI) tract. Preclinical studies have demonstrated the capacity to deliver small molecules, proteins, vaccines, and nucleic acids locally and systemically, validating further developmentof the system. | Series A / Mar 29, 2021 | ||
| See all 23 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Axil Capital invest in?
Axil Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 23 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Axil Capital's check size?
Axil Capital typically joins rounds of $9.8M–$55M at Series A, $7M–$150M at Series B and $3.1M–$62M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Axil Capital participates in.
How do I contact Axil Capital?
Public channels for Axil Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Axil Capital?
The team at Axil Capital includes Fred Shane (Managing Partner & Co-Founder) and Hiroshi Gonaikawa (Co-Founder & Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
